The UC Davis Cancer Center Animal Imaging (CCAl) Shared Resource addresses the growing importance of anatomic, functional and molecular imaging in cancer research by providing Cancer Center researchers access to state-of-the-art imaging equipment, novel targeted imaging tracers, experienced technical support personnel and support for data acquisition and analysis. The CCAl shared resource includes an unparalleled array of small and large animal (clinical) imaging technologies for minimally invasive and non-destructive morphologic and physiologic imaging. The resource is comprised of two inter-related facilities within the Department of Biomedical Engineering and the School of Veterinary Medicine Teaching Hospital that house a microPET, a cyclotron and radiopharmacy, gamma camera, small animal and large animal helical CT, clinical (1.5T) and high-field (7.0T) MRI, optical (bioluminescence) imaging, ultra-high frequency and clinical ultrasound, high-resolution low-energy radiography, clinical radiography and fluoroscopy, anesthesia and monitoring equipment and animal housing for both small and large animals. The objectives of the CCAl shared resource are: 1) Provide Cancer Center members direct access to a comprehensive, multimodality research imaging resource for studies involving induced cancer models in small animals (primarily mice and rats) 2) Provide Cancer Center members direct access to a comprehensive, multimodality research imaging resource for studies involving spontaneous and induced cancer models in large animals (dog, cat, pig, etc). 3) Design and synthesize novel imaging tracers for studies involving targeted tracer delivery. 4) Provide professional consultation to investigators for design of experimental studies. 5) Provide technical support to CC members for execution of animal imaging studies and for collection and analysis of data.
The UC Davis Cancer Center Animal Imaging (CCAl) Shared Resource facilitates cancer-related research involving small and large animal imaging thereby reducing costs, increasing efficiency and improving the productivity of Cancer Center researchers through thoughtful design, execution and analysis of imaging studies.
|Zhang, Jin; Lucchesi, Christopher; Chen, Xinbin (2016) A new function for p53 tetramerization domain in cell fate control. Cell Cycle 15:2854-2855|
|Vinall, Ruth L; Tepper, Clifford G; Ripoll, Alexandra A Z et al. (2016) Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes Cancer 7:86-97|
|Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2016) A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leuk Lymphoma 57:2307-14|
|TachÃ©, VÃ©ronique; Bivina, Liga; White, Sophie et al. (2016) Lipoyltransferase 1 Gene Defect Resulting in Fatal Lactic Acidosis in Two Siblings. Case Rep Obstet Gynecol 2016:6520148|
|Lara, Joshua; Brunson, Ann; Keegan, Theresa H M et al. (2016) Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol 196:1378-1382|
|Faisal, Farzana A; Sundi, Debasish; Tosoian, Jeffrey J et al. (2016) Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol 70:14-7|
|Dang, Julie H T; Chen Jr, Moon S (2016) Increasing Hepatitis B Testing and Linkage to Care of Foreign-Born Asians, Sacramento, California, 2012-2013. Public Health Rep 131 Suppl 2:119-24|
|Rowson-Hodel, Ashley R; Berg, Anastasia L; Wald, Jessica H et al. (2016) Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. Cancer Lett 375:62-72|
|Zhao, Yong; Tu, Mei-Juan; Wang, Wei-Peng et al. (2016) Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep 6:26611|
|Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40|
Showing the most recent 10 out of 608 publications